Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
doi: https://doi.org/10.1101/2022.03.03.22271827
Masaharu Shinkai
1Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Takuhiro Sonoyama
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Akari Kamitani
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Risa Shibata
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Naomi Seki
3Shionogi & Co., Ltd., Pharmaceutical Research Division 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
Shinya Omoto
3Shionogi & Co., Ltd., Pharmaceutical Research Division 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
Masahiro Shinoda
1Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Takashi Sato
1Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Naoki Ishii
4Department of Gastroenterology, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Kenji Igarashi
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Mari Ariyasu
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan

Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Posted April 01, 2022.
Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
medRxiv 2022.03.03.22271827; doi: https://doi.org/10.1101/2022.03.03.22271827
Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
medRxiv 2022.03.03.22271827; doi: https://doi.org/10.1101/2022.03.03.22271827
Subject Area
Subject Areas
- Addiction Medicine (427)
- Allergy and Immunology (753)
- Anesthesia (220)
- Cardiovascular Medicine (3285)
- Dermatology (276)
- Emergency Medicine (478)
- Epidemiology (13346)
- Forensic Medicine (19)
- Gastroenterology (898)
- Genetic and Genomic Medicine (5138)
- Geriatric Medicine (480)
- Health Economics (781)
- Health Informatics (3260)
- Health Policy (1140)
- Hematology (428)
- HIV/AIDS (1015)
- Medical Education (476)
- Medical Ethics (126)
- Nephrology (522)
- Neurology (4911)
- Nursing (262)
- Nutrition (725)
- Oncology (2517)
- Ophthalmology (722)
- Orthopedics (280)
- Otolaryngology (347)
- Pain Medicine (323)
- Palliative Medicine (90)
- Pathology (542)
- Pediatrics (1299)
- Primary Care Research (555)
- Public and Global Health (7489)
- Radiology and Imaging (1703)
- Respiratory Medicine (979)
- Rheumatology (479)
- Sports Medicine (424)
- Surgery (547)
- Toxicology (72)
- Transplantation (235)
- Urology (203)